Travere Therapeutics (TVTX) Total Non-Current Liabilities (2011 - 2026)

Travere Therapeutics' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $447.1 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 12.11% year-over-year to $447.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $447.1 million (down 12.11% YoY) and the FY2025 annual result came in at $482.8 million, down 8.61% from the prior year.
• Total Non-Current Liabilities was $447.1 million for Q1 2026 at Travere Therapeutics, down from $482.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $620.3 million in Q4 2022 and bottomed at $447.1 million in Q1 2026.
• A 5-year average of $535.2 million and a median of $543.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 70.28% — and 2026, when it slipped 12.11%.
• Travere Therapeutics' Total Non-Current Liabilities stood at $620.3 million in 2022, then decreased by 6.86% to $577.8 million in 2023, then declined by 8.57% to $528.3 million in 2024, then declined by 8.61% to $482.8 million in 2025, then dropped by 7.39% to $447.1 million in 2026.
• Business Quant data shows TVTX's Total Non-Current Liabilities at $447.1 million in Q1 2026, $482.8 million in Q4 2025, and $459.1 million in Q3 2025.